BioSpace News Archive

Business

Compugen Reports Third Quarter 2023 Results

Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.

November 7, 2023
·
13 min read
ChitogenX Launches Burn and Skin Repair Development Program

ChitogenX Inc. announced that it has launched a new development program targeting significant unmet medical needs in the burn and skin repair market, currently valued at US $19B and growing at 5% + CAGR through 2032.

November 7, 2023
·
3 min read
Genetown

Syndax Announces Participation at Stifel Healthcare Conference

Syndax Pharmaceuticals announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 4:45 p.m. ET.

November 7, 2023
·
1 min read
Biotech Bay

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.

November 7, 2023
·
1 min read
Biotech Beach

VedaBio Unveils World Class Scientific Advisory Board

VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, announced the formation of its scientific advisory board comprised of world class academic and industry experts Rashid Bashir, PhD, Daniel Durocher, PhD, Patrick Hsu, PhD and David Perlin, PhD.

November 7, 2023
·
4 min read
Genetown

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

Verastem Oncology announced results of the first-ever LGSOC Patient Impact Survey that reveal the particular challenges with diagnosis, disease management and mental, physical, and emotional well-being experienced by people living with low-grade serous ovarian cancer.

November 7, 2023
·
9 min read
Business

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2023.

November 7, 2023
·
15 min read
Business

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the third quarter ended September 30, 2023, including recent commercial and operational progress, and regulatory updates.

November 7, 2023
·
15 min read
Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

Lario Therapeutics has received the “CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” from the Loulou Foundation at the annual CDKL5 Forum.

November 7, 2023
·
4 min read
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

Repare Therapeutics Inc. announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.

November 7, 2023
·
2 min read